Tests to determine whether or not an individual is pregnant.
Methods of detecting pregnancy by examining the levels of human chorionic gonadotropin (HCG) in plasma or urine.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
A potentially life-threatening condition in which EMBRYO IMPLANTATION occurs outside the cavity of the UTERUS. Most ectopic pregnancies (>96%) occur in the FALLOPIAN TUBES, known as TUBAL PREGNANCY. They can be in other locations, such as UTERINE CERVIX; OVARY; and abdominal cavity (PREGNANCY, ABDOMINAL).
Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; SPONTANEOUS ABORTION; INDUCED ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO.
A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity (CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN).
The beta subunit of human CHORIONIC GONADOTROPIN. Its structure is similar to the beta subunit of LUTEINIZING HORMONE, except for the additional 30 amino acids at the carboxy end with the associated carbohydrate residues. HCG-beta is used as a diagnostic marker for early detection of pregnancy, spontaneous abortion (ABORTION, SPONTANEOUS); ECTOPIC PREGNANCY; HYDATIDIFORM MOLE; CHORIOCARCINOMA; or DOWN SYNDROME.
The ratio of the number of conceptions (CONCEPTION) including LIVE BIRTH; STILLBIRTH; and fetal losses, to the mean number of females of reproductive age in a population during a set time period.
An assisted reproductive technique that includes the direct handling and manipulation of oocytes and sperm to achieve fertilization in vitro.
Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases.
The transfer of mammalian embryos from an in vivo or in vitro environment to a suitable host to improve pregnancy or gestational outcome in human or animal. In human fertility treatment programs, preimplantation embryos ranging from the 4-cell stage to the blastocyst stage are transferred to the uterine cavity between 3-5 days after FERTILIZATION IN VITRO.
Positive test results in subjects who do not possess the attribute for which the test is conducted. The labeling of healthy persons as diseased when screening in the detection of disease. (Last, A Dictionary of Epidemiology, 2d ed)
The process of bearing developing young (EMBRYOS or FETUSES) in utero in non-human mammals, beginning from FERTILIZATION to BIRTH.
An assisted fertilization technique consisting of the microinjection of a single viable sperm into an extracted ovum. It is used principally to overcome low sperm count, low sperm motility, inability of sperm to penetrate the egg, or other conditions related to male infertility (INFERTILITY, MALE).
Commercially prepared reagent sets, with accessory devices, containing all of the major components and literature necessary to perform one or more designated diagnostic tests or procedures. They may be for laboratory or personal use.
The beginning third of a human PREGNANCY, from the first day of the last normal menstrual period (MENSTRUATION) through the completion of 14 weeks (98 days) of gestation.
The last third of a human PREGNANCY, from the beginning of the 29th through the 42nd completed week (197 to 294 days) of gestation.

Detection of early pregnancy forms of human chorionic gonadotropin by home pregnancy test devices. (1/21)

BACKGROUND: Home pregnancy testing devices claim >99% diagnostic accuracy for pregnancy and utility on the first day of the missed menses or earlier. We investigated the forms of human chorionic gonadotropin (hCG) in early pregnancy urines, the diagnostic accuracy claim, and the abilities of 15 devices to detect the different forms of hCG. METHODS: We measured the concentrations of regular hCG and hyperglycosylated hCG (H-hCG, a large hCG variant) in 592 urines. Fifteen home devices were tested according to manufacturers' instructions with regular hCG and H-hCG diluted in urine. RESULTS: H-hCG was the principal hCG-related molecule in pregnancy urine in the 2 weeks following the missed menses (61% and 50% of total immunoreactivity in the 4th and 5th completed weeks of pregnancy, respectively). Of 15 home test devices, 2 had a detection limit of 6.3 IU/L for regular hCG, but poorer detection of H-hCG. Two devices detected 13 IU/L regular hCG, one with similar detection and one with poorer detection of H-hCG. Ten devices detected 25 IU/L regular hCG, 6 with poorer detection of H-hCG. One device detected 50 IU/L regular hCG, but better detected H-hCG. Overall, 9 of 15 devices did not detect H-hCG as well as regular hCG. CONCLUSIONS: H-hCG is the principal hCG immunoreactivity in early pregnancy urine. Home tests vary widely in detection limits for regular hCG (6.3-50 IU/L), and 9 of 15 devices (60%) had poorer detection limits for H-hCG than for hCG. The variation in analytical detection limits appears contradictory to the common claim for all devices of >99% detection of pregnancy on the first day of the missed menses or earlier. We suggest that manufacturers calibrate devices for both hCG and H-hCG and determine the detection rates for pregnancy rather than the proportion of positive results at arbitrary hCG concentrations.  (+info)

The diagnosis of pregnancy in general practice. (2/21)

In 1,631 pregnancies presenting to general practitioners, the reliability of three proprietary slide tests for the diagnosis of pregnancy was assessed both against the outcome and against the results of hospital tests done at the same time. When all patients were considered the reliability of such tests done in the surgery was 85 per cent against a 90 per cent for hospital tests and when only patients who were more than 42 days pregnant were included, the accuracy figure rose to 87 per cent in general practice and 91 per cent in hospital.The time delay before the results of the hospital test was assessed showed a mean of three days which is considered unacceptable if there are urgent clinical reasons for the test being done. The doctors participating listed their reasons for doing tests and in 54 per cent of cases urgent confirmation or otherwise of the pregnancy was considered essential by either doctor or patient. In the remaining 46 per cent this confirmation was considered simply helpful rather than essential. The study showed that the accuracy of the test, when delegated to a nurse, was acceptable and that in a proportion of three to one the participating doctors considered that the test was of value and worthwhile in patient care.  (+info)

Implementation of universal antenatal screening for HIV and hepatitis B--lessons for future work. (3/21)

This paper describes the successful implementation of universal antenatal screening for HIV and hepatitis B in Southampton and South West Hampshire Health Authority. This was achieved through formation of a multi-disciplinary planning group of clinicians and managers from local trusts. The approach taken in implementing screening is described, key elements of this being the appointment of screening co-ordinators and consultation with local midwives to ensure their training needs were addressed. Lessons for future work are discussed.  (+info)

Radioimmunoassay of a bovine pregnancy-associated glycoprotein in serum: its application for pregnancy diagnosis. (4/21)

A sensitive and specific double-antibody RIA for a bovine pregnancy-associated glycoprotein (bPAG) is described. The limit of detection was 0.2 ng/ml. The assay was specific for bPAG in that pituitary and placental gonadotropic hormones and other placental or serum proteins assayed in serial dilutions did not cross-react. The RIA allowed measurement of bPAG in placental extracts, fetal serum, fetal fluids, and serum or plasma of pregnant cows. About 20% of unbred heifers and nonpregnant cows had detectable levels ranging from 0.30 +/- 0.09 to 0.50 +/- 0.17 ng/ml (mean +/- SD), and 15% of bull sera showed higher concentrations (3.01 +/- 1.73 ng/ml) of bPAG or bPAG-like protein. Variations among animals was observed in fetal serum bPAG concentrations. Bovine PAG was detected in maternal peripheral blood at Day 22 of pregnancy (mean +/- SD, 0.38 +/- 0.13 ng/ml) in some animals and at Day 30 in all pregnant cows. Peripheral serum bPAG levels increased progressively to 3.60 +/- 1.73 ng/ml (mean +/- SD) at Day 30 of pregnancy, to 24.53 +/- 8.81 ng/ml at Day 120, and to 1551.91 +/- 589.68 ng/ml at Day 270. Peak concentration of bPAG was 2462.42 +/- 1017.88 ng/ml and it occurred 1-5 days prior to parturition. After delivery, bPAG concentrations decreased steadily to 499.63 +/- 267.20 ng/ml at Day 14 postpartum (pp), 10.12 +/- 7.84 ng/ml at Day 60 pp, and 1.44 +/- 1.08 ng/ml at Day 90 pp. The undetectable concentration (less than 0.20 ng/ml) was reached by Day 100 +/- 20 pp. An investigation undertaken in Holstein heifers, Holstein cows, and Hereford cows used as recipients for purebred Holstein embryos supplied evidence of the influence of breed of recipient and sex of fetuses on peripheral concentrations of bPAG. A herd of 430 Holstein-Friesian heifers that had received transferred embryos were bled at Day 35 postestrus (pe) for measurement of bPAG. The bPAG was detected in 287 of 430 serum samples analyzed. By rectal palpation performed at Day 45 pe, 267 heifers with detectable levels of bPAG at Day 35 pe were confirmed to be pregnant as were 3 of 143 heifers previously diagnosed as not pregnant by RIA. These results suggest that detection of this placental-specific antigen in the serum could be used as a specific serological method for early pregnancy diagnosis in cattle from 28 days after breeding.  (+info)

Frequent false positive beta human chorionic gonadotropin tests in immunoglobulin A deficiency. (5/21)

A patient with IgA deficiency had a series of positive serum pregnancy tests which led to medical and surgical procedures for suspected molar pregnancy. These tests were found to be falsely positive due to heterophile antibody. The aim of this study was to determine the frequency of false positive betahCG assays in sera of IgA deficient patients. Sera from a panel of IgA deficient (IgA < 7 mg/dl) patients were tested for the presence of betaHCG using three different assays, and also for IgG anti-goat and anti-mouse antibodies. Patients were seen at Mount Sinai Medical Center and included 54 patients (ages 1-80 years, 32 females, 22 males) with IgA deficiency. Thirty percent of 54 IgA deficient patient sera yielded positive pregnancy tests by one or more of the three betahCG assays, however, none of the patients were pregnant. In comparison to sera of normal controls, 39% of the patient sera contained significant amounts of anti-goat antibody and 18% contained significant amounts of anti-mouse antibody. While heterophile antibodies are common in IgA deficient serum, false positive assays for betahCG in IgA deficient serum have not been previously reported. The possibility of false positive test results should be considered prior to invasive procedures in IgA deficient patients.  (+info)

Evaluation of early conception factor lateral flow test to determine nonpregnancy in dairy cattle. (6/21)

The early conception factor (ECF) lateral flow test was evaluated for its ability to accurately determine nonpregnant status in dairy cattle. Results of 2 field trials involving 191 cows and 832 tests indicated the probability that a cow can be correctly diagnosed as nonpregnant by using the ECF test is only about 50%. Agreement of test results between milk and serum obtained from the same cow was 57.5%. The ECF test was not consistent in identifying nonpregnancy when the same cows were tested repeatedly over a period of 4 weeks. We conclude that the ECF lateral flow test does not accurately identify nonpregnancy in dairy cattle.  (+info)

Concentration of bovine pregnancy associated glycoprotein in plasma and milk: its application for pregnancy diagnosis in cows. (7/21)

Pregnancy diagnosis is an important part in reproduction management of ruminants. The aim of the study was to use a new method for evaluating the bPAG and cPAG in milk and blood bPAG and compare this results with the other method for pregnancy diagnosis in the cows. The study was carried out in 220 Holstein Frisian cows. Heparinised blood samples were taken from the jugular vein and stored at -20 degrees C until PAG assay by RIA. For bPAG and cPAG, RIA test, milk samples were homogenized. Pure bPAG was used as a standard tracer described by Zoli et al. (1992). The cows were diagnosed as pregnant by means of USG (Aloka SSD 210) and by rectal palpation. bPAG and cPAG concentration in milk increased after 28 day of pregnancy and showed the rapid increase near the parturition. The same results of bPAG concentration we obtained in the blood samples. The decline of bPAG concentration was faster in the milk than in the blood. The data showed that the RIA method is precise enough to measure PAG concentrations in the maternal blood and milk of cows. The data indicate that milk samples can be used for pregnancy diagnosis in cows. The sensitivity and specificity of RIA measurement of PAG are very high.  (+info)

Comparison of commercial ELISA blood tests for early pregnancy detection in dairy cows. (8/21)

The objective of the present study was to compare two commercially available blood-based pregnancy tests, namely BioPRYN, an ELISA for pregnancy-specific protein B (PSPB), and an ELISA for pregnancy-associated glycoprotein (PAG), for early pregnancy diagnosis in dairy cattle using transrectal ultrasonography as a gold standard. Transrectal ultrasonography was conducted 26-58 days after artificial insemination (AI) in 197 cattle from 19 farms. Concurrently, a blood sample was collected for determination of serum PSPB and PAG. Transrectal palpation was performed approximately 120 days after AI to verify that pregnancy was maintained. For PSPB and PAG, there were no significant differences (P>0.05) in sensitivity (98.0 and 97.8%), specificity (97.1 and 91.2%), positive predictive values (99.3 and 97.8%), negative predictive values (91.9 and 91.2%) and accuracy (97.8 and 96.4%). In conclusion, the two blood pregnancy assays were equally efficacious and were highly accurate (based on transrectal ultrasonography as the gold standard).  (+info)

A pregnancy test is a medical diagnostic tool used to determine whether or not a woman is pregnant. These tests detect the presence of human chorionic gonadotropin (hCG), a hormone produced by the placenta after fertilization. Pregnancy tests can be performed using a variety of methods, including urine tests and blood tests.

Urine pregnancy tests are typically performed at home and involve either dipping a test strip into a sample of urine or holding the strip under a stream of urine for several seconds. The test strip contains antibodies that react with hCG, producing a visual signal such as a line or plus sign if hCG is present.

Blood pregnancy tests are performed by a healthcare provider and can detect lower levels of hCG than urine tests. There are two types of blood pregnancy tests: qualitative and quantitative. Qualitative tests simply detect the presence or absence of hCG, while quantitative tests measure the exact amount of hCG present in the blood.

Pregnancy tests are generally very accurate when used correctly, but false positives and false negatives can occur. False positives may occur due to certain medical conditions or medications that contain hCG. False negatives may occur if the test is taken too early or if it is not performed correctly. It is important to follow the instructions carefully and consult with a healthcare provider if there is any uncertainty about the results.

Immunologic pregnancy tests are a type of diagnostic test used to determine the presence of human chorionic gonadotropin (hCG) in a patient's urine or blood. hCG is a hormone produced by the placenta during pregnancy, and its levels increase rapidly in early pregnancy. Immunologic pregnancy tests use antibodies to detect the presence of hCG and produce a positive or negative result based on the amount of hCG detected. These tests are widely used as an initial screening tool for pregnancy and can provide accurate results within a few days of missed menstrual period.

Pregnancy is a physiological state or condition where a fertilized egg (zygote) successfully implants and grows in the uterus of a woman, leading to the development of an embryo and finally a fetus. This process typically spans approximately 40 weeks, divided into three trimesters, and culminates in childbirth. Throughout this period, numerous hormonal and physical changes occur to support the growing offspring, including uterine enlargement, breast development, and various maternal adaptations to ensure the fetus's optimal growth and well-being.

Ectopic pregnancy is a type of abnormal pregnancy that occurs outside the uterine cavity. The most common site for an ectopic pregnancy is the fallopian tube, accounting for about 95% of cases. This condition is also known as tubal pregnancy. Other less common sites include the ovary, cervix, and abdominal cavity.

In a normal pregnancy, the fertilized egg travels down the fallopian tube and implants itself in the lining of the uterus. However, in an ectopic pregnancy, the fertilized egg implants and starts to develop somewhere other than the uterus. The growing embryo cannot survive outside the uterus, and if left untreated, an ectopic pregnancy can cause life-threatening bleeding due to the rupture of the fallopian tube or other organs.

Symptoms of ectopic pregnancy may include abdominal pain, vaginal bleeding, shoulder pain, lightheadedness, fainting, and in severe cases, shock. Diagnosis is usually made through a combination of medical history, physical examination, ultrasound, and blood tests to measure the levels of human chorionic gonadotropin (hCG), a hormone produced during pregnancy.

Treatment for ectopic pregnancy depends on several factors, including the location, size, and growth rate of the ectopic mass, as well as the patient's overall health and desire for future pregnancies. Treatment options may include medication to stop the growth of the embryo or surgery to remove the ectopic tissue. In some cases, both methods may be used together. Early diagnosis and treatment can help prevent serious complications and improve the chances of preserving fertility in future pregnancies.

Pregnancy outcome refers to the final result or status of a pregnancy, including both the health of the mother and the newborn baby. It can be categorized into various types such as:

1. Live birth: The delivery of one or more babies who show signs of life after separation from their mother.
2. Stillbirth: The delivery of a baby who has died in the womb after 20 weeks of pregnancy.
3. Miscarriage: The spontaneous loss of a pregnancy before the 20th week.
4. Abortion: The intentional termination of a pregnancy before the fetus can survive outside the uterus.
5. Ectopic pregnancy: A pregnancy that develops outside the uterus, usually in the fallopian tube, which is not viable and requires medical attention.
6. Preterm birth: The delivery of a baby before 37 weeks of gestation, which can lead to various health issues for the newborn.
7. Full-term birth: The delivery of a baby between 37 and 42 weeks of gestation.
8. Post-term pregnancy: The delivery of a baby after 42 weeks of gestation, which may increase the risk of complications for both mother and baby.

The pregnancy outcome is influenced by various factors such as maternal age, health status, lifestyle habits, genetic factors, and access to quality prenatal care.

Chorionic Gonadotropin (hCG) is a hormone that is produced during pregnancy. It is produced by the placenta after implantation of the fertilized egg in the uterus. The main function of hCG is to prevent the disintegration of the corpus luteum, which is a temporary endocrine structure that forms in the ovary after ovulation and produces progesterone during early pregnancy. Progesterone is essential for maintaining the lining of the uterus and supporting the pregnancy.

hCG can be detected in the blood or urine as early as 10 days after conception, and its levels continue to rise throughout the first trimester of pregnancy. In addition to its role in maintaining pregnancy, hCG is also used as a clinical marker for pregnancy and to monitor certain medical conditions such as gestational trophoblastic diseases.

Chorionic Gonadotropin, beta Subunit, Human (β-hCG) is a protein that is produced by the placenta during pregnancy. It is a component of human chorionic gonadotropin (hCG), which is a hormone that is composed of two subunits: alpha and beta. The β-hCG subunit is specific to hCG and is not found in other hormones, making it a useful marker for pregnancy and certain medical conditions.

During early pregnancy, the levels of β-hCG increase rapidly and can be detected in the blood and urine. This has led to the development of pregnancy tests that detect the presence of β-hCG to confirm pregnancy. In addition to its role in pregnancy, β-hCG is also used as a tumor marker for certain types of cancer, such as germ cell tumors and choriocarcinoma.

Elevated levels of β-hCG may indicate the presence of a molar pregnancy, a condition in which a fertilized egg implants in the uterus but does not develop properly. In some cases, a molar pregnancy can become cancerous and require treatment. Therefore, monitoring β-hCG levels during pregnancy is important for detecting any potential complications.

The pregnancy rate is a measure used in reproductive medicine to determine the frequency or efficiency of conception following certain treatments, interventions, or under specific conditions. It is typically defined as the number of pregnancies per 100 women exposed to the condition being studied over a specified period of time. A pregnancy is confirmed when a woman has a positive result on a pregnancy test or through the detection of a gestational sac on an ultrasound exam.

In clinical trials and research, the pregnancy rate helps healthcare professionals evaluate the effectiveness of various fertility treatments such as in vitro fertilization (IVF), intrauterine insemination (IUI), or ovulation induction medications. The pregnancy rate can also be used to assess the impact of lifestyle factors, environmental exposures, or medical conditions on fertility and conception.

It is important to note that pregnancy rates may vary depending on several factors, including age, the cause of infertility, the type and quality of treatment provided, and individual patient characteristics. Therefore, comparing pregnancy rates between different studies should be done cautiously, considering these potential confounding variables.

Fertilization in vitro, also known as in-vitro fertilization (IVF), is a medical procedure where an egg (oocyte) and sperm are combined in a laboratory dish to facilitate fertilization. The fertilized egg (embryo) is then transferred to a uterus with the hope of establishing a successful pregnancy. This procedure is often used when other assisted reproductive technologies have been unsuccessful or are not applicable, such as in cases of blocked fallopian tubes, severe male factor infertility, and unexplained infertility. The process involves ovarian stimulation, egg retrieval, fertilization, embryo culture, and embryo transfer. In some cases, additional techniques such as intracytoplasmic sperm injection (ICSI) or preimplantation genetic testing (PGT) may be used to increase the chances of success.

Pregnancy complications refer to any health problems that arise during pregnancy which can put both the mother and the baby at risk. These complications may occur at any point during the pregnancy, from conception until childbirth. Some common pregnancy complications include:

1. Gestational diabetes: a type of diabetes that develops during pregnancy in women who did not have diabetes before becoming pregnant.
2. Preeclampsia: a pregnancy complication characterized by high blood pressure and damage to organs such as the liver or kidneys.
3. Placenta previa: a condition where the placenta covers the cervix, which can cause bleeding and may require delivery via cesarean section.
4. Preterm labor: when labor begins before 37 weeks of gestation, which can lead to premature birth and other complications.
5. Intrauterine growth restriction (IUGR): a condition where the fetus does not grow at a normal rate inside the womb.
6. Multiple pregnancies: carrying more than one baby, such as twins or triplets, which can increase the risk of premature labor and other complications.
7. Rh incompatibility: a condition where the mother's blood type is different from the baby's, which can cause anemia and jaundice in the newborn.
8. Pregnancy loss: including miscarriage, stillbirth, or ectopic pregnancy, which can be emotionally devastating for the parents.

It is important to monitor pregnancy closely and seek medical attention promptly if any concerning symptoms arise. With proper care and management, many pregnancy complications can be treated effectively, reducing the risk of harm to both the mother and the baby.

Embryo transfer is a medical procedure that involves the transfer of an embryo, which is typically created through in vitro fertilization (IVF), into the uterus of a woman with the aim of establishing a pregnancy. The embryo may be created using the intended parent's own sperm and eggs or those from donors. After fertilization and early cell division, the resulting embryo is transferred into the uterus of the recipient mother through a thin catheter that is inserted through the cervix. This procedure is typically performed under ultrasound guidance to ensure proper placement of the embryo. Embryo transfer is a key step in assisted reproductive technology (ART) and is often used as a treatment for infertility.

A "false positive reaction" in medical testing refers to a situation where a diagnostic test incorrectly indicates the presence of a specific condition or disease in an individual who does not actually have it. This occurs when the test results give a positive outcome, while the true health status of the person is negative or free from the condition being tested for.

False positive reactions can be caused by various factors including:

1. Presence of unrelated substances that interfere with the test result (e.g., cross-reactivity between similar molecules).
2. Low specificity of the test, which means it may detect other conditions or irrelevant factors as positive.
3. Contamination during sample collection, storage, or analysis.
4. Human errors in performing or interpreting the test results.

False positive reactions can have significant consequences, such as unnecessary treatments, anxiety, and increased healthcare costs. Therefore, it is essential to confirm any positive test result with additional tests or clinical evaluations before making a definitive diagnosis.

"Animal pregnancy" is not a term that is typically used in medical definitions. However, in biological terms, animal pregnancy refers to the condition where a fertilized egg (or eggs) implants and develops inside the reproductive tract of a female animal, leading to the birth of offspring (live young).

The specific details of animal pregnancy can vary widely between different species, with some animals exhibiting phenomena such as placental development, gestation periods, and hormonal changes that are similar to human pregnancy, while others may have very different reproductive strategies.

It's worth noting that the study of animal pregnancy and reproduction is an important area of biological research, as it can provide insights into fundamental mechanisms of embryonic development, genetics, and evolution.

Intracytoplasmic Sperm Injection (ICSI) is a specialized form of assisted reproductive technology (ART), specifically used in the context of in vitro fertilization (IVF). It involves the direct injection of a single sperm into the cytoplasm of a mature egg (oocyte) to facilitate fertilization. This technique is often used when there are issues with male infertility, such as low sperm count or poor sperm motility, to increase the chances of successful fertilization. The resulting embryos can then be transferred to the uterus in hopes of achieving a pregnancy.

Reagent kits, diagnostic are prepackaged sets of chemical reagents and other components designed for performing specific diagnostic tests or assays. These kits are often used in clinical laboratories to detect and measure the presence or absence of various biomarkers, such as proteins, antibodies, antigens, nucleic acids, or small molecules, in biological samples like blood, urine, or tissues.

Diagnostic reagent kits typically contain detailed instructions for their use, along with the necessary reagents, controls, and sometimes specialized equipment or supplies. They are designed to simplify the testing process, reduce human error, and increase standardization, ensuring accurate and reliable results. Examples of diagnostic reagent kits include those used for pregnancy tests, infectious disease screening, drug testing, genetic testing, and cancer biomarker detection.

The first trimester of pregnancy is defined as the period of gestational development that extends from conception (fertilization of the egg by sperm) to the end of the 13th week. This critical phase marks significant transformations in both the mother's body and the growing embryo/fetus.

During the first trimester, the fertilized egg implants into the uterine lining (implantation), initiating a series of complex interactions leading to the formation of the placenta - an organ essential for providing nutrients and oxygen to the developing fetus while removing waste products. Simultaneously, the embryo undergoes rapid cell division and differentiation, giving rise to various organs and systems. By the end of the first trimester, most major structures are present, although they continue to mature and grow throughout pregnancy.

The mother may experience several physiological changes during this time, including:
- Morning sickness (nausea and vomiting)
- Fatigue
- Breast tenderness
- Frequent urination
- Food aversions or cravings
- Mood swings

Additionally, hormonal shifts can cause various symptoms and prepare the body for potential changes in lactation, posture, and pelvic alignment as pregnancy progresses. Regular prenatal care is crucial during this period to monitor both maternal and fetal wellbeing, identify any potential complications early on, and provide appropriate guidance and support throughout the pregnancy.

The third trimester of pregnancy is the final stage of pregnancy that lasts from week 29 until birth, which typically occurs around the 40th week. During this period, the fetus continues to grow and mature, gaining weight rapidly. The mother's body also prepares for childbirth by dilating the cervix and producing milk in preparation for breastfeeding. Regular prenatal care is crucial during this time to monitor the health of both the mother and the developing fetus, as well as to prepare for delivery.

Early pregnancy loss is defined as the termination of pregnancy before 20 weeks gestation or with a fetal weight of below 500 ... Immunologic causes. Tests for antiphospholipid antibodies (APLAs), signaling the presence of the autoimmune disease ... Immunologic Causes. Autoimmune Abnormalities. Recurrent pregnancy loss is associated with several autoimmune diseases. One such ... However, couples in whom pregnancy loss can be attributed to a balanced translocation may benefit from specific genetic testing ...
SEE ALSO: enzyme-linked immunosorbent assay, radioimmunoassay, radioimmunoelectrophoresis, immunologic pregnancy test. SYN: ... under test. single i. gel diffusion precipitin tests in one dimension, under test, gel diffusion precipitin tests in two ... double i. gel diffusion precipitin tests in two dimensions, under test. radial i. (RID) gel diffusion precipitin tests in one ... Prevention or interference with the development of immunologic response; may reflect natural immunologic unresponsiveness ( ...
Immunologic pregnancy tests were introduced in 1960 when Wide and Gemzell presented a test based on in-vitro hemagglutination ... This was a first step away from in-vivo pregnancy testing and initiated a series of improvements in pregnancy testing leading ... A Thin Blue Line: The History of the Pregnancy Test Kit. "A Timeline of Pregnancy Testing". National Institutes of Health. ... but not for its usage as a functional pregnancy test. Hormonal pregnancy tests such as Primodos and Duogynon were used in the ...
Because pregnancy can reduce immunologic responsiveness, consider serologic testing to document a protective immune response to ... Pregnancy. Safety of YF vaccination during pregnancy has not been studied in any large prospective trials. In 2 observational ... more specific antibody testing (e.g., a plaque reduction neutralization test) should be performed to confirm the infection. ... Perform virus isolation or nucleic acid amplification tests for YF virus or YF viral RNA early in the course of the illness. By ...
Health-care providers should counsel and offer HIV testing to women as early in pregnancy as possible so that informed and ... virologic and immunologic tests when performed, and c) clinical follow-up. Uncertainties regarding HIV infection status, ... testing (50-52). Mandatory testing may increase the potential for negative consequences of HIV testing and result in some women ... than in clinics that use a nondirective approach to HIV testing (i.e, patients are told the test is available, but testing is ...
Multiple miscarriage is defined by the loss of two or more clinical pregnancies. Of all pregnancies, 15-20% end in miscarriage. ... Immunological Tests. Blood tests to check for immunologic responses that can cause pregnancy loss include antithyroid ... What is Recurrent Pregnancy Loss? Recurrent pregnancy loss is defined by the loss of two or more clinical pregnancies. A ... There are also blood tests that check for protective blocking factors. These are essential to protect the pregnancy from being ...
Public Health Service Recommendations for Human Immunodeficiency Virus Counseling and Voluntary Testing for Pregnant Women ... Health-care providers should counsel and offer HIV testing to women as early in pregnancy as possible so that informed and ... results from additional virologic and immunologic tests when performed, and c) clinical follow-up. Uncertainties regarding HIV ... but testing is neither encouraged nor discouraged) (52). Laboratory Testing Considerations The HIV-1 testing algorithm ...
... of the Act and from the provisions of this Regulation with respect only to the performance of immunologic tests for pregnancy. ... 5. That a Hepatitis B surface antigen test not be performed if the person requesting the test indicates that the test is for a ... test or any combination of them not be performed if the person requesting the test indicates that the test is for a fetal ... cystic fibrosis or severe combined immune deficiency not be performed if the person requesting the test indicates that the test ...
... of the Act and from the provisions of this Regulation with respect only to the performance of immunologic tests for pregnancy. ... 5. That a Hepatitis B surface antigen test not be performed if the person requesting the test indicates that the test is for a ... test or any combination of them not be performed if the person requesting the test indicates that the test is for a fetal ... iii) at the request of an insurer or an agent within the meaning of the Insurance Act, in respect of HIV Antibody testing, ...
Positive pregnancy test before and during the study. - Maintenance therapy with any drug, or significant history or drug ... neurologic, psychiatric, endocrine, immunologic or dermatologic disease. - Females who are pregnant, lactating or are likely to ... Positive results to HIV, HBsAg or anti-HCV tests. Locations and Contacts. Algorithme Pharma, Laval, Quebec H7V 4B4, Canada ... this range, they must be without any clinical significance(laboratory tests are presented in section 6. 1.1. 3) - Healthy ...
15120 Pregnancy test, immunologic - urine 14004 Full service gp-obstet delivery bonus-w delivery ... Tests Performed in a Physicians Office The following tests are only payable when performed in your office. These tests are not ... You can only claim 00012 if after taking the test you send it to another physicians office or a laboratory (i.e., only when ... The following test is payable in a physicians office (when performed on their own patients) and/or on a referral basis: ...
Pregnancy Tests, Immunologic E5.478.594.662. Preoptic Area A8.186.211.730.385.357.342.450 A8.186.211.730.317.357.342.450. Pro- ... Hemadsorption Inhibition Tests E5.478.594.760.360. Hemagglutination Inhibition Tests E5.478.594.760.370. Hemagglutination Tests ... Cytotoxicity Tests, Immunologic E5.478.245 E5.478.594.160. Death, Sudden, Cardiac C14.280.67.441. Decidua A16.759.289 A16.710. ... Immunologic Tests E5.478.594. Immunophenotyping E5.478.600 E1.450.495.447. E5.478.594.450. Immunoradiometric Assay E5.478. ...
Pregnancy Tests, Immunologic E5.478.594.662. Preoptic Area A8.186.211.730.385.357.342.450 A8.186.211.730.317.357.342.450. Pro- ... Hemadsorption Inhibition Tests E5.478.594.760.360. Hemagglutination Inhibition Tests E5.478.594.760.370. Hemagglutination Tests ... Cytotoxicity Tests, Immunologic E5.478.245 E5.478.594.160. Death, Sudden, Cardiac C14.280.67.441. Decidua A16.759.289 A16.710. ... Immunologic Tests E5.478.594. Immunophenotyping E5.478.600 E1.450.495.447. E5.478.594.450. Immunoradiometric Assay E5.478. ...
Pregnancy Tests, Immunologic E5.478.594.662. Preoptic Area A8.186.211.730.385.357.342.450 A8.186.211.730.317.357.342.450. Pro- ... Hemadsorption Inhibition Tests E5.478.594.760.360. Hemagglutination Inhibition Tests E5.478.594.760.370. Hemagglutination Tests ... Cytotoxicity Tests, Immunologic E5.478.245 E5.478.594.160. Death, Sudden, Cardiac C14.280.67.441. Decidua A16.759.289 A16.710. ... Immunologic Tests E5.478.594. Immunophenotyping E5.478.600 E1.450.495.447. E5.478.594.450. Immunoradiometric Assay E5.478. ...
Pregnancy Tests, Immunologic E5.478.594.662. Preoptic Area A8.186.211.730.385.357.342.450 A8.186.211.730.317.357.342.450. Pro- ... Hemadsorption Inhibition Tests E5.478.594.760.360. Hemagglutination Inhibition Tests E5.478.594.760.370. Hemagglutination Tests ... Cytotoxicity Tests, Immunologic E5.478.245 E5.478.594.160. Death, Sudden, Cardiac C14.280.67.441. Decidua A16.759.289 A16.710. ... Immunologic Tests E5.478.594. Immunophenotyping E5.478.600 E1.450.495.447. E5.478.594.450. Immunoradiometric Assay E5.478. ...
Pregnancy Tests, Immunologic E5.478.594.662. Preoptic Area A8.186.211.730.385.357.342.450 A8.186.211.730.317.357.342.450. Pro- ... Hemadsorption Inhibition Tests E5.478.594.760.360. Hemagglutination Inhibition Tests E5.478.594.760.370. Hemagglutination Tests ... Cytotoxicity Tests, Immunologic E5.478.245 E5.478.594.160. Death, Sudden, Cardiac C14.280.67.441. Decidua A16.759.289 A16.710. ... Immunologic Tests E5.478.594. Immunophenotyping E5.478.600 E1.450.495.447. E5.478.594.450. Immunoradiometric Assay E5.478. ...
Pregnancy Tests, Immunologic E5.478.594.662. Preoptic Area A8.186.211.730.385.357.342.450 A8.186.211.730.317.357.342.450. Pro- ... Hemadsorption Inhibition Tests E5.478.594.760.360. Hemagglutination Inhibition Tests E5.478.594.760.370. Hemagglutination Tests ... Cytotoxicity Tests, Immunologic E5.478.245 E5.478.594.160. Death, Sudden, Cardiac C14.280.67.441. Decidua A16.759.289 A16.710. ... Immunologic Tests E5.478.594. Immunophenotyping E5.478.600 E1.450.495.447. E5.478.594.450. Immunoradiometric Assay E5.478. ...
Pregnancy Tests, Immunologic E5.478.594.662. Preoptic Area A8.186.211.730.385.357.342.450 A8.186.211.730.317.357.342.450. Pro- ... Hemadsorption Inhibition Tests E5.478.594.760.360. Hemagglutination Inhibition Tests E5.478.594.760.370. Hemagglutination Tests ... Cytotoxicity Tests, Immunologic E5.478.245 E5.478.594.160. Death, Sudden, Cardiac C14.280.67.441. Decidua A16.759.289 A16.710. ... Immunologic Tests E5.478.594. Immunophenotyping E5.478.600 E1.450.495.447. E5.478.594.450. Immunoradiometric Assay E5.478. ...
Pregnancy Tests, Immunologic E5.478.594.662. Preoptic Area A8.186.211.730.385.357.342.450 A8.186.211.730.317.357.342.450. Pro- ... Hemadsorption Inhibition Tests E5.478.594.760.360. Hemagglutination Inhibition Tests E5.478.594.760.370. Hemagglutination Tests ... Cytotoxicity Tests, Immunologic E5.478.245 E5.478.594.160. Death, Sudden, Cardiac C14.280.67.441. Decidua A16.759.289 A16.710. ... Immunologic Tests E5.478.594. Immunophenotyping E5.478.600 E1.450.495.447. E5.478.594.450. Immunoradiometric Assay E5.478. ...
Pregnancy Tests, Immunologic E5.478.594.662. Preoptic Area A8.186.211.730.385.357.342.450 A8.186.211.730.317.357.342.450. Pro- ... Hemadsorption Inhibition Tests E5.478.594.760.360. Hemagglutination Inhibition Tests E5.478.594.760.370. Hemagglutination Tests ... Cytotoxicity Tests, Immunologic E5.478.245 E5.478.594.160. Death, Sudden, Cardiac C14.280.67.441. Decidua A16.759.289 A16.710. ... Immunologic Tests E5.478.594. Immunophenotyping E5.478.600 E1.450.495.447. E5.478.594.450. Immunoradiometric Assay E5.478. ...
Pregnancy Tests, Immunologic E5.478.594.662. Preoptic Area A8.186.211.730.385.357.342.450 A8.186.211.730.317.357.342.450. Pro- ... Hemadsorption Inhibition Tests E5.478.594.760.360. Hemagglutination Inhibition Tests E5.478.594.760.370. Hemagglutination Tests ... Cytotoxicity Tests, Immunologic E5.478.245 E5.478.594.160. Death, Sudden, Cardiac C14.280.67.441. Decidua A16.759.289 A16.710. ... Immunologic Tests E5.478.594. Immunophenotyping E5.478.600 E1.450.495.447. E5.478.594.450. Immunoradiometric Assay E5.478. ...
Pregnancy Tests, Immunologic E5.478.594.662. Preoptic Area A8.186.211.730.385.357.342.450 A8.186.211.730.317.357.342.450. Pro- ... Hemadsorption Inhibition Tests E5.478.594.760.360. Hemagglutination Inhibition Tests E5.478.594.760.370. Hemagglutination Tests ... Cytotoxicity Tests, Immunologic E5.478.245 E5.478.594.160. Death, Sudden, Cardiac C14.280.67.441. Decidua A16.759.289 A16.710. ... Immunologic Tests E5.478.594. Immunophenotyping E5.478.600 E1.450.495.447. E5.478.594.450. Immunoradiometric Assay E5.478. ...
Negative pregnancy test. - Fertile patients must use effective barrier contraception during and for 3 months. after study ... At least 3 weeks since prior immunologic therapy directed at the malignant tumor. - No concurrent biologic therapy or ...
Most of these tests, which are called point-of-care (POC) tests, use the lateral flow architecture. Pregnancy tests are a ... 12 thoughts on "Coronavirus Testing Follow-Up: Rapid Immunologic Testing" * Dan says: ... I could find no indication of an immunologic test for COVID-19 (more specifically, a test for SARS-Cov-2, the virus that causes ... The immunologic test tells you where its been and who might already have immunities. Both are valuable but in different ways. ...
Your healthcare provider should do a pregnancy test to see if you are pregnant before starting RUXIENCE. ... The B-cell counts returned to normal levels, and immunologic function was restored within 6 months postpartum. ... 8.1 Pregnancy. Risk Summary Based on human data, rituximab products can cause adverse developmental outcomes including B-cell ... Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The background risk of ...
Objectives: This study was conducted to evaluate whether exposure to air pollution is associated with immunologic responses in ... Serum and cervico-vaginal cytokines were compared using Wilcoxon signed-ranks test and Spearman rank correlations for select ... Background: Environmental exposures are associated with a number of outcomes including adverse pregnancy outcomes. Although ... Systemic inflammatory markers may provide information on immunologic processes and response to environmental exposures, but are ...
Because pregnancy may affect immunologic function, serologic testing can be considered to document a protective immune response ... Pregnancy. Pregnancy is a precaution to receiving YF vaccine. The safety of YF vaccination during pregnancy has not been ... Virus isolation or nucleic acid amplification tests performed early in the illness for YF virus or YF viral RNA. By the time ... The infant tested positive for YF viral RNA and died of fulminant YF on the 12th day of life. ...
... and other factors such as pregnancy. Identifying and addressing psychosocial barriers to care is a key element of ensuring long ... even before the results of baseline HIV drug-resistance testing are available. Initial ART selection should be guided by co- ... After the diagnosis is confirmed, comprehensive testing should be ordered (Table 2).4,20 Testing should include primary care ... 20 Durable suppression of viremia facilitates immunologic recovery and may mitigate HIV-associated inflammation and immune ...
When a fertilized egg implants and develops outside the uteruss main cavity, an ectopic pregnancy results. Most frequently, a ... Fertilized eggs are the first step in pregnancy. The fertilized egg normally adheres to the uterine lining. ... Ectopic Pregnancy: Diagnosis The diagnosis of ectopic pregnancy is mainly done based on history and some of the tests may be ... Many local variables, including those that are poisonous, viral, immunologic, and hormonal, can cause inflammation. After a ...
Can autoimmune disease cause miscarriage or immunologic testing help me?. Yes! Autoimmune disease can cause recurrent pregnancy ... When patients are tracking their cycles and pregnancy tests closer they may notice these subtitles and early pregnancy failures ... What other reasons can cause RPL or recurrent pregnancy loss?. Recurrent pregnancy loss or RPL is defined by American Society ... 15-25% of pregnancies can end in miscarriage. RPL occurs in only 5% of women with 2 losses and women with 3 or more losses in ...

No FAQ available that match "pregnancy tests immunologic"

No images available that match "pregnancy tests immunologic"